Grade 3 puts a clear cell kidney cancer in the higher-risk half of the grading scale. Its cells look more abnormal than those of a grade 1 or 2 tumor, and it is more likely to return. Grade is only one part of the outlook, though. For a cancer still inside the kidney that has been removed, most people do well for years. The other details on the same report, and the option of extra treatment after surgery, can shift the odds meaningfully.
What Grade 3 Means on Your Pathology Report
Your report will usually say “WHO/ISUP grade,” the standard four-level scale pathologists use for clear cell kidney cancer.1PubMed Central. The ISUP system of staging, grading and classification of renal cell neoplasia The scale rates a small dot inside each cell’s center by how easily it can be seen.1PubMed Central. The ISUP system of staging, grading and classification of renal cell neoplasia In grade 3 these dots are clearly visible even at low magnification, while in grades 1 and 2 they need high power or are barely seen.1PubMed Central. The ISUP system of staging, grading and classification of renal cell neoplasia Grade 4 is reserved for very bizarre cells or areas your report may call sarcomatoid or rhabdoid, so grade 3 sits below the most aggressive form.1PubMed Central. The ISUP system of staging, grading and classification of renal cell neoplasia Doctors group grades 1 and 2 as low grade, and grades 3 and 4 as high grade.
To assign the grade, the pathologist scans the stained tissue slide, starting at low power and moving to high power, looking for the areas where these dots are most prominent. The grade comes from the worst area found. It is a judgment about the most abnormal part of the sample, not an average across the whole tumor. Many tumors contain both low and high grade areas, so a grade 3 label may describe only a portion of yours.
Grade and stage are two different words on the report. Grade is how the cells look. Stage is how big the tumor is and where it has spread, written as T, N and M codes, usually near the grade line. A small grade 3 tumor inside the kidney can carry a better outlook than a large low-grade one that has spread, so ask your doctor which stage you have before reading any survival number.
If your surgery was before about 2016, the report may use the older Fuhrman grade. Fuhrman grade 3 is broadly similar to WHO/ISUP grade 3, and many survival studies mix both systems, so the numbers still apply roughly.
Survival Rates for Grade 3 Clear Cell Kidney Cancer
In US cancer registry data covering all stages, about 63% of people with grade 3 or 4 clear cell cancer were alive five years after diagnosis.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis That compares with about 83% for grade 1 and 66% for grade 2.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis The typical survival time for grade 3 to 4 was about 114 months, roughly nine and a half years, similar to grade 2.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis
That median is a midpoint: half the group lived longer and half shorter, so it is not a prediction for any one person. Registry medians also include older patients who died of unrelated causes, so they understate how long many younger patients live.
Confined tumors show a clearer grade effect. Among people whose tumor was still inside the kidney, about 60% of those with grade 3 to 4 were alive and free of kidney cancer death at five years, versus 96% for grade 1.3PubMed. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients That series is older and small, and it grouped grade 3 with the more aggressive grade 4. Most studies lump the two together, and because grade 4 does worse, it pulls the combined number down. Grade 3 on its own is likely somewhat better than the lumped figures.
The two sets of figures can’t be lined up side by side. The first counts all causes of death in everyone at every stage, while the second counts only kidney cancer deaths in people whose cancer had not spread. Compare grades only within the same set, such as 83%, 66% and 63% from the same registry.
A five-year figure describes groups diagnosed years ago, before newer treatments. Surviving past five years is common, so it is not a deadline. It doesn’t say whether the cancer came back and was treated, since someone living with recurrent cancer still counts as alive, and it says nothing about quality of life.
Why Stage Matters More Than Grade
About 68% of people with clear cell cancer limited to the kidney were alive at five years.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis This fell to about 58% when it had spread to nearby tissue or lymph nodes, and to about 19% when it had spread to distant organs.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis For a grade 3 tumor that was removed while still confined, the localized figures are the most relevant.
The 58% group combines several situations, such as growth into fat around the kidney and involvement of lymph nodes, that do not carry identical risks. Your report’s pT and N lines show which applies to you.
To find your stage, look for the pT number. pT1 and pT2 mean the cancer is confined to the kidney. N0 and M0 mean no spread to lymph nodes or distant organs. Ask whether your scans before surgery showed any spread.
Other personal factors also count. Age, sex, and whether surgery was done each independently affected survival alongside grade and stage.4PubMed Central. Prognosis of clear cell renal cell carcinoma patients stratified by age: A research relied on SEER database People 65 and older had about four times the risk of death of those under 45, much of it from other illnesses.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis Having grade 3 to 4 raised the risk of death by about 45% compared with grade 1 after accounting for these factors.2Journal of Cancer. Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis
Surgery shows up as its own factor partly because it is the main cure for kidney cancer that hasn’t spread widely. People who did not have it were often those whose cancer was too advanced or who were too ill to operate on. So the surgery effect partly reflects how sick the person was to begin with. If your tumor has already been removed, you are in the group with the better outlook on this factor.
Other Report Findings That Change a Grade 3 Outlook
Many reports note tumor necrosis, areas of dead tissue inside the tumor.5PubMed Central. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy In grade 3 tumors without necrosis, about 62% were alive without kidney cancer death at ten years.5PubMed Central. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy With necrosis, that fell to about 30%.5PubMed Central. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy
Look for “tumor necrosis” or “necrosis present/absent” in the microscopic findings; some reports state it only in the description, not in a summary line. If it isn’t mentioned, ask whether it was checked and absent or simply not reported. Because it separates two very different grade 3 groups, it can change how closely you are followed and whether treatment after surgery is discussed.
Dead areas often appear when a tumor outgrows its blood supply, which is why necrosis is read as a sign of aggressive behavior. It does not mean the cancer has spread.
Cancer cells seen inside small blood vessels raise the chance of recurrence, especially combined with high grade.6PubMed Central. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis It suggests the tumor had a route out of the kidney, but it is a finding about risk, not proof that cells have traveled or settled elsewhere. A marker on some tumor cells is more often found in high-grade tumors and linked to earlier return.7PubMed Central. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer8PubMed Central. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma
About 1 in 10 clear cell tumors carries a change in a gene called BAP1.9Clinical Cancer Research. Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network These tumors are nearly always high grade and tend to behave more aggressively.10PubMed Central. The expanding role of BAP1 in clear cell renal cell carcinoma11PubMed. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations In confined cancer, typical survival was about 4.6 years with BAP1 changes versus 10.6 years with a more common PBRM1 change.10PubMed Central. The expanding role of BAP1 in clear cell renal cell carcinoma Gene testing is not routine for confined cancer, so many reports won’t include it.
Doctors may also combine stage, size, grade and necrosis into a score such as the Leibovich score, which sorts patients into low, intermediate or high risk of return. Ask which group you fall in; it guides follow-up and extra treatment.
Treatment After Surgery to Lower the Risk of Return
Treatment after surgery aims to kill any cancer left behind. Surgery removes the visible tumor, but tiny groups of cells may already have traveled and can’t be seen on scans. Treatment aims at those hidden cells before they grow into tumors that show up later. Because of this, the benefit is measured as fewer recurrences in a group.
In a large trial, 77% on the immunotherapy drug pembrolizumab were cancer-free at two years versus 68% on placebo.12PubMed. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma At four years, 91% on pembrolizumab were alive versus 86% on placebo.13PubMed Central. Role of Systemic Therapy in Localized Renal Cell Carcinoma: Where Do We Stand and Where Are We Heading? It is now a standard option for clear cell cancer at increased risk of return.14PubMed. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Most people in both arms were cancer-free at two years, so many would have done well without the drug, and no one can tell in advance who will be helped.
In that trial, increased risk included grade 3 or 4 with a pT2 tumor, any pT3 or larger tumor, or lymph node spread. A small pT1 grade 3 tumor generally did not qualify. Ask your oncologist whether your stage and grade meet these criteria.
The treatment is an infusion every three or six weeks for about a year. It works by helping the immune system attack cancer cells. Side effects can include tiredness, rash, and thyroid or bowel inflammation, and some are lasting, so benefit has to be weighed against risk with your doctor.
Where It Can Come Back and How You’ll Be Monitored
When confined kidney cancer comes back, the lungs, bones and the other kidney are among the most common first sites.15PubMed Central. Incidence and Pattern of Recurrence after Surgical Resection in Organ-Confined Renal Cell Carcinoma That is why follow-up scans usually cover the chest and abdomen.
For higher-risk tumors, scans of the chest and abdomen often happen every three to six months at first, then space out to yearly after a few years. Most returns appear in the first three to five years. Blood tests check kidney function, since one kidney now does the work.
A new tumor in the remaining kidney can be a fresh cancer, not necessarily a spread of the first. Ask your doctor about protecting your remaining kidney, for example by being careful with certain pain medicines.
Between scans, report a new persistent cough or coughing blood, new bone pain that doesn’t settle, unexplained weight loss, or blood in the urine. Don’t wait for the next scan.
How Certain Is a Grade 3 Diagnosis
Two pathologists looking at the same tumor often give different grades, especially between grade 2 and 3.16PubMed. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma17PubMed Central. WHO/ISUP grading of clear cell renal cell carcinoma and papillary renal cell carcinoma; validation of grading on the digital pathology platform and perspectives on reproducibility of grade More than half of tumors contain two grades mixed together.16PubMed. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma Examining more of the tumor uncovered high-grade areas in many tumors first called low grade,18BJUI. Grade heterogeneity in clear cell renal cell carcinoma so some tumors called low grade may behave worse than expected.19BJUI. Grade heterogeneity in clear cell renal cell carcinoma Agreement is better when grouping low versus high grade.16PubMed. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma20International Journal of Pathology and Clinical Research. A New Grading for Clear Cell Renal Cell Carcinoma: Combined WHO/ISUP Grading System
Only part of a large tumor is placed on slides, so a small high-grade area may be missed. Because the grade follows the worst area found, more thorough sampling can only raise the grade, not lower it. It is reasonable to ask how much of the tumor was examined.
A needle biopsy before surgery samples only a tiny part, so its grade can differ from the final surgical grade.21Preprints. Radiomics Machine Learning Analysis of Clear Cell Renal Cell Carcinoma for Tumour Grade Prediction Based on Intra-tumoural Subregion Heterogeneity Scan-based methods to predict grade are being studied but are not yet routine.22PubMed. CT-based radiomics stratification of tumor grade and TNM stage of clear cell renal cell carcinoma A move between grades 2 and 3 can change the group from low to high, which affects how closely you are followed.
You can request a review at a center specializing in kidney cancer. It matters most if grade affects your eligibility for treatment after surgery. Ask your team to send the slides; you usually don’t need new tests.

